SANINFRA (Sanmit Infra Ltd) Share Analysis 2025: Segments, Results, SHP, Risks & Long‑Term Outlook
- Company Overview & Segments
- Results Timeline (FY22 → FY25 → Q1 FY26)
- Latest Results: Q4 FY25 & Q1 FY26
- Balance Sheet (Mar 2025)
- Shareholding Pattern (2025)
- Key Ratios & Quality Checks
- Recent Quarterly Snapshot
- Business Drivers & Moat
- Outlook 2025–2030
- Risks & Monitorables
- SWOT Analysis
- FAQs
- Internal & External Links
- Disclaimer
1) Company Overview & Segments
Sanmit Infra Limited (SANINFRA) is a small‑cap, multi‑segment company operating across Realty & Infrastructure, Petroleum and related products (bitumen, LDO/furnace oil, lubricants), Biomedical waste recycling/disinfection machinery, and Bitumen emulsion / road‑construction materials. This segment mix is confirmed in public profiles and company literature. 0
2) Results Timeline (FY22 → FY25 → Q1 FY26)
- FY22–FY23: Trading‑led operations with thin margins; biomedical/infra orders lumpy (as per historic summaries in public trackers).
- FY24: Annual report published (AGM Sep 28, 2024); company proposed a small dividend (₹0.04 declared Sep 20, 2024, per MC corporate actions). 1
- FY25 (Apr 2024–Mar 2025): Momentum improved into Q4 FY25 with stronger YoY growth. 2
- Q1 FY26 (Jun 2025): Board approved unaudited results on Aug 13, 2025; net profit reported at ~₹0.94 cr (+1,780% YoY). 3
- Corporate development (FY26): Tolling agreement dated Jun 30, 2025 with IndianOil Tota Pvt. Ltd. (manufacturing/handling) as per exchange filing. 4
3) Latest Results — Q4 FY25 & Q1 FY26
Q4 FY25 (Quarter ended Mar 2025)
| Metric | Q4 FY25 | YoY |
|---|---|---|
| Total Revenue | ₹45.92 cr | +106.99% |
| Operating Income (EBIT) | ₹2.28 cr | +309.64% |
| PAT | ₹1.59 cr | +195.31% |
| OPM (approx.) | ~4.9–5.3% | ↑ YoY |
Source: LiveMint result card (Mar 2025). 5
Q1 FY26 (Quarter ended Jun 2025)
| Metric | Q1 FY26 | YoY |
|---|---|---|
| Sales / Total Income | ₹39.01 cr | +74.07% |
| PAT | ₹0.94 cr | +1,780% |
| OPM (approx.) | ~5.1% | Stable |
Source: Business Standard / Capital Market live news (Aug 14–15, 2025). Board approval & limited review note filed Aug 13, 2025. 6
4) Balance Sheet Highlights (as of Mar 2025)
| Item | Mar 2025 | Comment |
|---|---|---|
| Equity Share Capital | ₹15.80 cr | FV ₹1 |
| Reserves & Surplus | ₹20.87 cr | Improved YoY (rounded) |
| Total Shareholders’ Funds | ₹36.67 cr | Growth with retained earnings |
Pulled from Moneycontrol/BSE summaries; exact figures in AR & filings. 7
5) Shareholding Pattern (2025)
- Promoters: ~72.33% (Jun 2025) — stable; pledging 0%. 8
- Public/Retail: ~27.67% (Jun 2025). 9
- FII/DII/MF: ~0% each (Jun 2025). 10
- BSE‑only listing: Code 532435; NSE not traded; ISIN INE799C01031. 11
6) Key Ratios & Quality Checks
- Profitability: Trading‑heavy mix → thin OPM (c.~4–6% recent), improving with scale. (Cross‑check quarterly margins above.) 12
- Working Capital: Growth phases can stretch receivables/inventory; keep an eye on quarterly notes.
- Leverage: Low‑to‑moderate; largely WC linked (monitor borrowings vs sales).
- Corporate actions: Small dividend declared in Sep 2024 (₹0.04). 13
7) Recent Quarterly Snapshot (last five)
| Quarter | Total Income / Sales (₹ cr) | PAT (₹ cr) |
|---|---|---|
| Jun ’25 (Q1 FY26) | ~40.18 / 39.01 | ~0.94 |
| Mar ’25 (Q4 FY25) | 45.92 | 1.59 |
| Dec ’24 (Q3 FY25) | 36.39 | 0.34 |
| Sep ’24 (Q2 FY25) | 41.14 | -0.42 |
| Jun ’24 (Q1 FY25) | 23.11 / 22.41 | 0.05 |
Compiled from Moneycontrol/Economic Times/Business Standard/LiveMint snapshots; minor rounding differences exist between portals. 14
8) Business Drivers & Moat (Practical View)
- Petroleum & Road Materials: Volume + commodity spread drive top line/gross margin; disciplined receivables crucial.
- Infra/Realty: Milestone‑linked recognition → lumpy revenues; approvals and execution timings matter.
- Biomedical Equipment: Niche orders (hospitals/municipalities) can lift blended margins; tender timelines cause quarterly swings.
- Corporate agreements: Tolling/manufacturing pacts (e.g., Jun 30, 2025 filing) may support utilization and scale. 15
9) Outlook 2025–2030
Base case: **top‑line growth** led by petroleum/road‑materials volumes; **margin improvement** driven by (i) pricing spreads, (ii) higher‑mix biomedical & emulsion businesses, (iii) tighter working capital. Execution discipline (order quality, receivables, vendor terms) will determine whether OPM can sustain above the ~5% zone over cycles.
10) Risks & Monitorables
- Commodity & pricing risk (bitumen, FO/LDO spreads) compressing margins.
- Tender/order timing causing quarterly volatility, especially in biomedical/infra.
- Receivables/Inventory stretch in growth phases; watch cash conversion and debt.
- Small‑cap & liquidity (BSE‑only) → higher price swings.
- Governance hygiene — track related‑party transactions and board changes in filings. 16
11) SWOT Analysis
Strengths
- Diverse revenue avenues (petroleum, infra, biomedical) create optionality.
- Improved YoY performance in Q4 FY25 & Q1 FY26. 17
Weaknesses
- Thin trading margins; modest ROE/ROCE.
- Working‑capital intensity; receivable discipline critical.
Opportunities
- Scaling bitumen emulsion/road materials (value‑add).
- Biomedical orders from hospitals/ULBs; tender pipelines.
- Operational pacts (tolling/processing) to improve utilization. 18
Threats
- Commodity down‑cycle; regulatory changes in health/environment.
- Execution slippages and WC stress in rapid scale‑up.
12) FAQs on SANINFRA
Q1) Kya SANINFRA NSE pe listed hai?
Nahi—yeh BSE‑listed hai (Code 532435); NSE par trading nahi hoti. ISIN: INE799C01031. 19
Q2) Q1 FY26 me profit kitna tha?
~₹0.94 crore (YoY +1,780%); Sales ~₹39.01 crore. Board ne 13 Aug 2025 ko results approve kiye. 20
Q3) Promoter holding kitni hai?
~72.33% (Jun 2025), pledge 0%. Retail ~27.67%. 21
Q4) Dividend diya tha?
Yes—Sep 20, 2024 ko ₹0.04 declare hua (FY24). 22
13) Internal & External Links
Internal (News‑Network.in)
- The Psychology of Stock Market
- Top 10 Best Indian Stocks to Invest
- Top 10 Booming Stocks in India 2025
External (Official/Trusted)
- Screener – Company page & filings 23
- Moneycontrol – Quarterly results 24
- LiveMint – Q4 FY25 card 25
- Business Standard – Q1 FY26 headline 26
- BSE filing – Limited review (13 Aug 2025) 27
- BSE filing – Tolling agreement (10 Jul 2025) 28
- Annual Report FY2023–24 (PDF) 29
- Yahoo Finance – Company profile 30
- LiveMint – Shareholding (Jun 2025) 31
14) Disclaimer
Yeh article sirf educational purpose ke liye hai; yeh investment advice nahi hai. Small‑caps me volatility aur liquidity risk zyada hota hai. Apna research (DYOR) karein aur zarurat ho to SEBI‑registered advisor se salaah lein. Numbers rounded hain aur 21 Aug 2025 tak ke public disclosures par adharit hain; naye filings aane par figures badal sakti hain.
0 Comments